The present invention relates to the use of cannabidiol (CBD), a phytocannabinoid which is naturally produced by Cannabis sativa plants or can be made synthetically, for use in combination with antibiotics. Preferably the CBD increases the bactericidal action of antibiotics. More preferably the bactericidal action is used against Gram-negative bacteria. In a further embodiment the CBD increases the antibiotic effects of Kanamycin in Gram-positive bacteria. Such combinations may help overcome antibiotic resistance. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. In particular tetrahydrocannabinol (THC) has been substantially removed to a level of not more than 0.1% (w/w). Alternatively, it is a synthetically produced CBD. In use the CBD is used concomitantly with one or more antibiotics. Alternatively, the CBD may be formulated for administration separately, sequentially or simultaneously with one or more antibiotics or the combination may be provided in a single dosage form. Where the CBD is formulated for administration separately, sequentially or simultaneously it may be provided as a kit or together with instructions to administer the one or more components in the manner indicated.La présente invention concerne l'utilisation de cannabidiol (CBD), un phytocannabinoïde naturellement produit par des plantes de Cannabis sativa ou qui peut être fabriqué de manière synthétique, destiné à être utilisé en combinaison avec des antibiotiques. Le CBD augmente de préférence l'action bactéricide des antibiotiques. L'action bactéricide est utilisée de préférence contre les bactéries à Gram négatif. Dans un autre mode de réalisation, le CBD augmente les effets antibiotiques de la kanamycine dans des bactéries à Gram positif. De telles combinaisons peuvent contribuer à surmonter la résistance aux antibiotiques. Le
